Diagnostics
Ceftralis Injection delivers broad-spectrum and reliable antibacterial therapy for patients suffering from severe bacterial infections. Formulated with Ceftriaxone, a third-generation cephalosporin, it works by inhibiting bacterial cell wall synthesis, ensuring rapid bactericidal activity against a wide range of Gram-positive and Gram-negative organisms. Its long half-life allows once-daily dosing, improving patient compliance and reducing hospital workload.
Ceftralis is highly effective in the treatment of community-acquired and hospital-acquired pneumonia, urinary tract infections, septicemia, intra-abdominal infections, skin and soft tissue infections, bone and joint infections, and meningitis. It is also used for surgical prophylaxis and in treating infections caused by multidrug-resistant organisms.
Backed by clinical evidence, Ceftralis demonstrates high cure rates, rapid fever control, and accelerated recovery in critical care patients. Its parenteral formulation ensures precise dosing, optimal bioavailability, and dependable outcomes in both inpatient and outpatient settings.
Research & Clinical Data for Ceftralis
Indications Supported by Evidence
- Respiratory Infections (CAP, HAP, Bronchitis): Significant improvement in bacterial clearance and lung function recovery.
- Meningitis: Proven efficacy in reducing morbidity and mortality, with excellent CNS penetration.
- Septicemia & Severe Infections: Demonstrated rapid reduction in systemic infection markers.
- Urinary Tract Infections: High clinical success rates, even in complicated UTIs.
- Intra-Abdominal & Surgical Infections: Effective coverage in peritonitis, appendicitis, and surgical prophylaxis.
- Skin, Soft Tissue, Bone & Joint Infections: Reliable outcomes in cellulitis, osteomyelitis, and wound infections.
Ceftralis Injection is a trusted, hospital-grade antibiotic that ensures rapid infection control, enhanced recovery, and superior patient outcomes with proven safety and efficacy.